JP2015511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511632A5
JP2015511632A5 JP2015502543A JP2015502543A JP2015511632A5 JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5 JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015502543 A JP2015502543 A JP 2015502543A JP 2015511632 A5 JP2015511632 A5 JP 2015511632A5
Authority
JP
Japan
Prior art keywords
melanoma
trifluoromethyl
amino
treatment
raf inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/052556 external-priority patent/WO2013144923A1/en
Publication of JP2015511632A publication Critical patent/JP2015511632A/ja
Publication of JP2015511632A5 publication Critical patent/JP2015511632A5/ja
Pending legal-status Critical Current

Links

JP2015502543A 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与 Pending JP2015511632A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618006P 2012-03-30 2012-03-30
US61/618,006 2012-03-30
PCT/IB2013/052556 WO2013144923A1 (en) 2012-03-30 2013-03-29 Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma

Publications (2)

Publication Number Publication Date
JP2015511632A JP2015511632A (ja) 2015-04-20
JP2015511632A5 true JP2015511632A5 (enExample) 2016-06-02

Family

ID=48326371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502543A Pending JP2015511632A (ja) 2012-03-30 2013-03-29 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Country Status (6)

Country Link
US (1) US20150126533A1 (enExample)
EP (1) EP2830664A1 (enExample)
JP (1) JP2015511632A (enExample)
CN (1) CN104428001A (enExample)
CA (1) CA2868954A1 (enExample)
WO (1) WO2013144923A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036942B1 (ru) 2013-11-11 2021-01-18 Эмджен Инк. Применение amg232 в комбинации с цитарабином или децитабином для лечения острого миелогенного лейкоза
UY36046A (es) 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CA2972189A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
CN107205933A (zh) * 2014-12-23 2017-09-26 米伦纽姆医药公司 Raf抑制剂与aurora激酶抑制剂的组合
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN115023230A (zh) * 2019-11-27 2022-09-06 首日生物制药公司 泛raf激酶抑制剂的固体分散体
CN117042772A (zh) * 2020-11-06 2023-11-10 首日生物制药公司 用于治疗低级别胶质瘤的raf抑制剂
KR20230107606A (ko) * 2020-11-06 2023-07-17 데이 원 바이오파마슈티칼즈, 인크. 저등급 신경교종 치료를 위한 raf 억제제
MX2023009642A (es) * 2021-02-19 2023-10-16 Day One Biopharmaceuticals Inc Combinacion de inhibidor de raf e inhibidor de mek.
CN117177754A (zh) * 2021-02-19 2023-12-05 首日生物制药公司 Raf抑制剂和mek抑制剂的组合

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
PL3560498T3 (pl) * 2009-10-16 2022-12-12 Novartis Ag Kombinacja zawierająca inhibitor mek i inhibitor b-raf
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
JP2015511632A5 (enExample)
UA113157C2 (xx) Спосіб лікування з використанням селективних інгібіторів bcl-2
JP2012530705A5 (enExample)
EP3641754A4 (en) COMPOSITIONS AND TREATMENTS AGAINST SLEEP DISORDERS
NO2017023I1 (no) Venetoklaks, dvs. 4-(4-{[2-(4-klorfenyl)-4,4-dimetylsykloheks-1-en-1-yl]metyl}piperazin-1-yl)-N-({3-nitro-4[{tetrahydro-2H-pyran-4-ylmetyl)amino]fenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloksy)benzamid
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
MA55571A (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
HRP20170638T1 (hr) MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI
JP2010526777A5 (enExample)
JP2014524362A5 (enExample)
JP2012516292A5 (enExample)
JP2014062126A5 (enExample)
JP2015517350A5 (enExample)
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
JP2015533163A5 (enExample)
JP2014530840A5 (enExample)
JP2016528011A5 (enExample)
LT3544976T (lt) N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
CN109563082A (zh) 核磁共振显像化合物、其中间体、核磁共振显像剂及应用、以及核磁共振成像方法
EP3558256A4 (en) BODY CARE COMPOSITIONS WITH GLUTATHION PRECURSOR WITH NICOTINAMIDE AND AMINO ACIDS
JP2014518212A5 (ja) 化合物及び組成物
JP2013538856A5 (enExample)
PL3544977T3 (pl) Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki